← Eichor
Study identifier: NCT04631471 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Regeneration in Cervical Degenerative Myelopathy

Condition: Myelopathy · Spinal Cord Diseases  ·  Sponsor: Cambridge University Hospitals NHS Foundation Trust

PhasePhase 3
Planned participants400
Who can joinAll sexes, 18 Years to 80 Years
Healthy volunteersNo

About this study

Degenerative (wear and tear arthritis of the spine) Cervical (concerning the neck) Myelopathy (injury to the spinal cord), DCM, is the most common spinal cord disorder of adulthood. In DCM, arthritis of the spine causes compression of the spinal cord. The symptoms of DCM are often mistaken for natural consequences of ageing, including numb and clumsy hands, loss of coordination, imbalance, bladder and bowel problems. The weakness can progress to severe paralysis. Every year approximately 4 individuals in 100,000 undergo surgery for DCM; however, many more individuals are thought to suffer from DCM. The main treatment for DCM is surgery. The aim of surgery is to create space and remove the compression of the spinal cord. This is known to prevent further injury. Unfortunately, the post-operative improvements are often incomplete and many patients remain severely disabled. Improving outcome after surgery represents an important unmet clinical need. Clinical and preclinical findings indicate that the drug Ibudilast can stimulate neuroprotective and regenerative processes in the spinal cord. Ibudilast is well-tolerated and used to treat asthma and post-stroke dizziness in Japan and is currently being investigated for use in treating other neurological diseases. This study will investigate whether daily oral administration of Ibudilast for a maximum of 34 weeks can improve hand function, strength, balance, urinary problems and reduce pain. The study will initially be conducted…

This description comes directly from the study's public registry record.

Talk to the study team

Mark R Kotter, PhD  ·  +44 1223 747476  ·  mrk25@cam.ac.uk

Paula Kareclas, PhD  ·  01223254684  ·  paula.kareclas@addenbrookes.nhs.uk

Always discuss trial participation with your own doctor first.

Locations (1)

Addenbrooke's HospitalCambridge, United KingdomRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04631471